Trials
Regulations
Contact Us

Welcome to pediculosis.com

Pediculosis.com is the world's only website aimed specifically at researchers, product managers and buyers in the head lice industry.

We provide regularly-updated information on new products, industry changes, regulatory issues, clinical trials and studies to help you identify emerging global trends and business opportunities.

btn-readmore

Industry News

      

Scientific News

newsimg-ind

newsimg-sci

14.12.12 | New funding and efficacy data for Hatchtech

Hatchtech, Pty Ltd have announced the completion of their financing round and published new data on the active ingredient in their DeOvo pediculicide product.

13.12.12 | TyraTech receives Product Registration in UK

TyraTech, Inc, has received notification from the UK regualtory body that their VaMOUSSE!™ head lice product has been registered as a medical device.

13.09.12 | Successful End-Of-Phase-2 consultations for DeOvo

The anti-lice product DeOvo, developed by Hatchtech Pty Ltd, has successfully completed its end-of-phase II consultations with the FDA.

24.08.12 | Sklice now available by prescription in the US

Sanofi Pasteur announced this week that Sklice, their ivermectin-based head lice treatment is now commercially available by prescription in the US.

27.07.12 | DeOvo granted patent by US PTO

The active ingredient in the DeOvo head lice treatment, produced by Hatchtech Pty Ltd, has been granted a patent by the US Patent and Trademark Office.

11.03.13 | More on Ivermectin and safety

Following the recent publication of clinical trial data showing Ivermectin solution to be a safe and effective pediculicide, two further recent items of note:

29.01.13 | New study on insecticide resistance in lice

 A recently-published study has found high occurrance of a genetic mutation in a lice sample which correlates with resistance to permethrin and malathion treatments.

04.01.13 | Ivermectin in vivo study results

A recently published study has found that ivermectin solution has strong in vivo pediculicide properties.

13.12.12 | FDA rejects lindane ban petition

A petition requesting that lindane be withdrawn from sale as a second-line pediculicide has been denied by the US Food and Drug Administration (FDA).

13.12.12 | Commentary and response on spinosad clinical trial

An assessment and author response to a 2009 clinical trial of spinosad has been published in Archives of Dermatology.

morenews-ind.png morenews-sci.png
  • Licecomb Engineering
  • Company News
  • Scientific News
  • Regulatory News
  • Clinical Trials
  • Pediculosis.com: The world's only specialist website for the head lice industry

Join us on Twitter

Site Map   |    Privacy Policy   |   Terms & Conditions

© 2012-2013 pediculosis.com — all rights reserved